Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kenemans

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Fertility and Sterility|September 13, 2003
Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac functionTatjana E Vogelvang, Marius J van der Mooren, Otto Kamp, et al.
Menopause (New York, N.Y.)|January 13, 2004
Homocysteine impairs estrogen-induced vasodilation in isolated rat arteriolesRaimond G V Smolders, Pieter Sipkema, Peter Kenemans, et al.
Fertility and Sterility|April 14, 2007
Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal womenMarieke O Verhoeven, Tom Teerlink, Peter Kenemans, et al.
Fertility and Sterility|April 4, 2006
Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal womenMajoie Hemelaar, Peter Kenemans, Lut de Bie, et al.
Cancer Letters|August 19, 2007
High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)María Moreno, Hetty J Bontkes, Rik J Scheper, et al.
American Journal of Obstetrics and Gynecology|October 6, 2005
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Journal of Cancer Research and Clinical Oncology|September 21, 2002
Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot studyIwona van Zanten-Przybysz, Carla Molthoff, Jacqueline Klein Gebbinck, et al.
Gynecologic Oncology|August 2, 2003
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesisJurgen M J Piek, René H M Verheijen, Peter Kenemans, et al.
Menopause (New York, N.Y.)|September 16, 2008
The influence of physiological and surgical menopause on coronary heart disease risk markersMarieke O Verhoeven, Marius J van der Mooren, Tom Teerlink, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 19, 2007
Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of lifeHenk R Franke, Monique M A Brood-van Zanten, Curt W Burger, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Fertility and Sterility|September 13, 2003
Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac functionTatjana E Vogelvang, Marius J van der Mooren, Otto Kamp, et al.
Menopause (New York, N.Y.)|January 13, 2004
Homocysteine impairs estrogen-induced vasodilation in isolated rat arteriolesRaimond G V Smolders, Pieter Sipkema, Peter Kenemans, et al.
Fertility and Sterility|April 14, 2007
Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal womenMarieke O Verhoeven, Tom Teerlink, Peter Kenemans, et al.
Fertility and Sterility|April 4, 2006
Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal womenMajoie Hemelaar, Peter Kenemans, Lut de Bie, et al.
Cancer Letters|August 19, 2007
High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)María Moreno, Hetty J Bontkes, Rik J Scheper, et al.
American Journal of Obstetrics and Gynecology|October 6, 2005
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Journal of Cancer Research and Clinical Oncology|September 21, 2002
Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot studyIwona van Zanten-Przybysz, Carla Molthoff, Jacqueline Klein Gebbinck, et al.
Gynecologic Oncology|August 2, 2003
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesisJurgen M J Piek, René H M Verheijen, Peter Kenemans, et al.
Menopause (New York, N.Y.)|September 16, 2008
The influence of physiological and surgical menopause on coronary heart disease risk markersMarieke O Verhoeven, Marius J van der Mooren, Tom Teerlink, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 19, 2007
Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of lifeHenk R Franke, Monique M A Brood-van Zanten, Curt W Burger, et al.
Pageof 7